Join us for an in-depth discussion on the latest developments in wet age-related macular degeneration treatment. We’re partnering with the American Society of Retina Specialists (ASRS) to bring you an overview of current treatment options, the impact of the Avastin shortage, and alternative treatments. We will also explore advocacy efforts by ASRS and the American Academy of Ophthalmology to address these issues.
Charles C. Wykoff, MD, PhD is Director of Research at Retina Consultants of Texas; Chairman of Research, Retina Consultants of America; Deputy Chair of Ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital; and Clinical Professor of Ophthalmology, Weill Cornell Medical College. He received his baccalaureate from MIT, PhD from Oxford University while on a Marshall Scholarship, MD from Harvard Medical School and completed retina fellowship at Bascom Palmer Eye Institute where he served as Chief Resident/Co-Director of Ocular Trauma and received a Heed Fellowship and the Ronald G. Michels Award.
He is passionate about translational research and accelerating drug and device development. He has published over 325 peer-reviewed manuscripts and serves on multiple scientific and medical advisory boards, safety monitoring committees, and global steering committees for endeavors spanning the innovative process from early to late-stage developments. He serves on the ASRS Executive Committee and Board of Directors, is a founding member of the Ophthalmology Retina Editorial Board, and a past President of the Vit-Buckle Society for which he is an Emeritus member of the Board of Trustees. He is a member of the NEI Audacious Goals Steering Committee and has been awarded multiple Achievement, Honor and Senior Honor Awards including the ASRS Young Investigator and the AAO Secretariat Awards. His guiding philosophy is to build and strengthen innovative, ethical teams focused on developing new approaches to improving outcomes for patients with blinding diseases.
About BrightFocus Foundation
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Through its flagship research programs — Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research— the Foundation has awarded nearly $300 million in groundbreaking research funding over the past 51 years and shares the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
